Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2025 09:27 ET | Source: Spherix Global Insights

Evolving Treatment Landscape for Chronic Spontaneous Urticaria Highlights Significant Unmet Needs and Expanding Opportunities for Therapeutic Innovation

EXTON, PA, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Chronic spontaneous urticaria (CSU), marked by unpredictable and often debilitating flare patterns, continues to impose a significant burden on patients...
September 25, 2025 08:30 ET | Source: Tiziana Life Sciences Ltd.

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor...
September 17, 2025 07:15 ET | Source: Arch Biopartners

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly...
August 21, 2025 09:12 ET | Source: Spherix Global Insights

Critical Inflection Point in FSGS on the Horizon with Nephrologists Poised to Rapidly Adopt New Therapies, According to Spherix Global Insights

EXTON, PA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for focal segmental glomerulosclerosis (FSGS), a rare and often progressive kidney disease, is approaching a critical inflection...
July 29, 2025 13:51 ET | Source: Spherix Global Insights

Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights

EXTON, PA, July 29, 2025 (GLOBE NEWSWIRE) -- According to new findings from Spherix Global Insights’ syndicated Market Dynamix™ service, hematologists managing patients with warm autoimmune...
July 22, 2025 07:30 ET | Source: Arch Biopartners

Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled...
July 17, 2025 09:37 ET | Source: Spherix Global Insights

Diverging Treatment Goals Emerge Between Hematologists and Nephrologists in aHUS Care, According to Spherix Global Insights

EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global Insights explores the nuanced dynamics between hematologists and...
July 08, 2025 14:22 ET | Source: Spherix Global Insights

Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights

EXTON, PA, July 08, 2025 (GLOBE NEWSWIRE) -- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or gender, though it is most...
June 21, 2025 06:20 ET | Source: ICPO Foundation

ICPO Foundation ist Co-Founder der RLT Angels Association mit dem Ziel, den Zugang zur Radiotheranostik für eine Million PatientInnen auszubauen

Weitere Gründungsmitglieder sind die European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis und RayzeBio, ein Unternehmen von Bristol Myers Squibb. Wiesbaden, 21. Juni 2025 – Die...
June 21, 2025 06:20 ET | Source: ICPO Foundation

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company. Wiesbaden, June 21, 2025 – The...